Xencor (NASDAQ: XNCR)
Xencor Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Xencor Company Info
Xencor, Inc. is a biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.
News & Analysis
Why Shares of Zencor Rose This Week
The clinical-stage biotech has seen its shares rise since a company presentation a few weeks ago.
2 Top Cancer Treatment Stocks To Watch In July
These hidden gems have the potential to deliver significant returns to their shareholders over the long run.
6 September Healthcare IPOs Investors Should Take Stock Of
The recent crop of new stocks runs the gamut from R&D stage biotech to a Fortune 500 spin-off with billions in revenue.
3 Top Biotech Stocks to Buy Right Now
If you're looking to buy biotech stocks, put these at the top of your list.
3 Top Healthcare Stocks to Buy Right Now
A large-cap big pharma, a mid-cap specialized care provider, and a small-cap biotech stand out as great healthcare stocks.
3 Top Biotech Stocks to Buy Right Now
These drug stocks are prescribing some serious growth potential in the years to come.
3 Top Biotech Stocks to Buy in April
Biotech stocks are falling, and that could be creating an opportunity to buy shares in these top companies.
[TIMESENSITIVE] 3 Biotech Stocks to Buy in February
These biotech stocks could put on a clinic in your investment portfolio.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.